Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Jörg Wissel & Songjin Ri. (2022) Assessment, goal setting, and botulinum neurotoxin a therapy in the management of post-stroke spastic movement disorder: updated perspectives on best practice. Expert Review of Neurotherapeutics 22:1, pages 27-42.
Read now
Read now
Hitoshi Kagaya, Yoshihisa Masakado, Eiichi Saitoh, Toshiyuki Fujiwara, Masahiro Abo, Shin-ichi Izumi, Hiroyuki Nodera, Andrzej Dekundy, Reinhard Hiersemenzel, Christiane Martina Nalaskowski, Angelika Hanschmann & Ryuji Kaji. (2020) IncobotulinumtoxinA for upper- and lower-limb spasticity in Japanese patients. Current Medical Research and Opinion 36:5, pages 827-834.
Read now
Read now
Michael Barnes, Serdar Kocer, Manuel Murie Fernandez, Jovita Balcaitiene & Klemens Fheodoroff. (2017) An international survey of patients living with spasticity. Disability and Rehabilitation 39:14, pages 1428-1434.
Read now
Read now
Andrea Santamato. (2016) Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity. Neuropsychiatric Disease and Treatment 12, pages 251-263.
Read now
Read now
Michelle Kaku & David M Simpson. (2016) Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity. Drug Design, Development and Therapy 10, pages 1085-1099.
Read now
Read now
Kirsten E. Zeuner & Günther Deuschl. (2016) Pharmacokinetics and pharmacodynamics of incobotulinumtoxinA influencing the clinical efficacy in post-stroke spasticity. Expert Opinion on Drug Metabolism & Toxicology 12:4, pages 457-466.
Read now
Read now
Wolfgang H Jost, Reiner Benecke, Dieter Hauschke, Joseph Jankovic, Petr Kaňovský, Peter Roggenkämper, David M Simpson & Cynthia L Comella. (2015) Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Design, Development and Therapy 9, pages 1913-1926.
Read now
Read now
Articles from other publishers (33)
Jorge Jacinto, Alexander Balbert, Djamel Bensmail, Stefano Carda, Nathalie Draulans, Thierry Deltombe, Nicholas Ketchum, Franco Molteni & Rajiv Reebye. (2023) Selecting Goals and Target Muscles for Botulinum Toxin A Injection Using the Goal Oriented Facilitated Approach to Spasticity Treatment (GO-FAST) Tool. Toxins 15:12, pages 676.
Crossref
Crossref
Amber L. LaMarcaMatthias J. KrennMolly A. Kelso-TrassKathryn C. MacDonaldCristina C. DemeoStanley F. Bazarek & Justin M. Brown. (2023) Selective Tibial Neurotomy Outcomes for Spastic Equinovarus Foot: Patient Expectations and Functional Assessment. Neurosurgery 93:5, pages 1026-1035.
Crossref
Crossref
Riccardo Marvulli, Maurizio Ranieri, Laura Belinda Rizzo, Francesco Marra, Giancarlo Ianieri & Marisa Megna. (2023) Clinical Onset of Action of Incobotulinum Toxin A Preparation. CNS & Neurological Disorders - Drug Targets 22:6, pages 916-923.
Crossref
Crossref
Djamel Bensmail, Pierre Karam, Anne Forestier, Jean-Yves Loze & Jonathan Lévy. (2023) Trends in Botulinum Toxin Use among Patients with Multiple Sclerosis: A Population-Based Study. Toxins 15:4, pages 280.
Crossref
Crossref
Tobias Bäumer & Sebastian Löns. (2022) Behandlung der Armspastik – Schritt für Schritt. Neurologie up2date 05:03, pages 208-215.
Crossref
Crossref
Steven Escaldi, Francesca Bianchi, Ganesh Bavikatte, Franco Molteni, Susana Moraleda, Thierry Deltombe & Gerard E Francisco. (2022) Module 1. The Journal of the International Society of Physical and Rehabilitation Medicine 5:Suppl 1, pages S3-S22.
Crossref
Crossref
Yoshihisa Masakado, Hitoshi Kagaya, Kunitsugu Kondo, Yohei Otaka, Andrzej Dekundy, Angelika Hanschmann, Thorin L. Geister & Ryuji Kaji. (2022) Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects. Frontiers in Neurology 13.
Crossref
Crossref
Zachary Bohart, Charles Cassidy, David Merrill, Mario Villani, Rosanna Villani, Leo Cappabianca & Mark Pitkin. (2022) Temporary Botulinum Immobilization of Residuum Muscles for Facilitation of the Initial Ingrowth of Skin to the Porous Skin and Bone Integrated Pylon in the Technology of Direct Skeletal Attachment: Large Animal Model. Frontiers in Rehabilitation Sciences 3.
Crossref
Crossref
Po-Cheng Hsu, Ke-Vin Chang, Yi-Hsiang Chiu, Wei-Ting Wu & Levent Özçakar. (2022) Comparative Effectiveness of Botulinum Toxin Injections and Extracorporeal Shockwave Therapy for Post-Stroke Spasticity: A Systematic Review and Network Meta-Analysis. eClinicalMedicine 43, pages 101222.
Crossref
Crossref
Chi Wang Ip, Axel Schramm, Pascal Maisonobe, Emma Zaragatski & Thomas Sycha. (2021) Behandlungszufriedenheit bei Patienten mit zervikaler DystonieTreatment satisfaction in patients with cervical dystonia. Der Nervenarzt 92:12, pages 1268-1275.
Crossref
Crossref
Andrea SANTAMATO, Salvatore FACCIORUSSO, Stefania SPINA, Nicoletta CINONE, Christian AVVANTAGGIATO, Luigi SANTORO, Chiara CIRITELLA, Nicola SMANIA, Alessandro PICELLI, Giulio GASPERINI, Franco MOLTENI, Alessio BARICICH & Pietro FIORE. (2021) Discontinuation of botulinum neurotoxin type-A treatment during COVID-19 pandemic: an Italian survey in post stroke and traumatic brain injury patients living with spasticity. European Journal of Physical and Rehabilitation Medicine 57:3.
Crossref
Crossref
Thavasimuthu Nisha Mol, Nitish Kamble, Vikram V. Holla, Rohan Mahale, Pramod Kumar Pal & Ravi Yadav. (2021) Patient Knowledge, Attitude and Perceptions towards Botulinum Toxin Treatment for Movement Disorders in India. Journal of Movement Disorders 14:2, pages 126-132.
Crossref
Crossref
André Lee, Jabreel Al-Sarea & Eckart Altenmüller. (2021) Nonlinear Changes in Botulinum Toxin Treatment of Task-Specific Dystonia during Long-Term Treatment. Toxins 13:6, pages 371.
Crossref
Crossref
Petr Kaňovský, Elie P. Elovic, Angelika Hanschmann, Irena Pulte, Michael Althaus, Reinhard Hiersemenzel & Christina Marciniak. (2021) Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis. Frontiers in Neurology 11.
Crossref
Crossref
Gerard E. Francisco, Jörg Wissel, Thomas Platz & Sheng Li. 2021. Clinical Pathways in Stroke Rehabilitation. Clinical Pathways in Stroke Rehabilitation
149
173
.
Alberto Esquenazi, Mauricio R. Delgado, Robert A. Hauser, Philippe Picaut, Keith Foster, Andreas Lysandropoulos & Jean-Michel Gracies. (2020) Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies. Frontiers in Neurology 11.
Crossref
Crossref
Yoshihisa Masakado, Masahiro Abo, Kunitsugu Kondo, Satoru Saeki, Eiichi Saitoh, Andrzej Dekundy, Angelika Hanschmann & Ryuji Kaji. (2020) Efficacy and safety of incobotulinumtoxinA in post-stroke upper-limb spasticity in Japanese subjects: results from a randomized, double-blind, placebo-controlled study (J-PURE). Journal of Neurology 267:7, pages 2029-2041.
Crossref
Crossref
Domenico Intiso, Valentina Simone, Michelangelo Bartolo, Andrea Santamato, Maurizio Ranieri, Maria Teresa Gatta & Filomena Di Rienzo. (2020) High Dosage of Botulinum Toxin Type A in Adult Subjects with Spasticity Following Acquired Central Nervous System Damage: Where Are We at?. Toxins 12:5, pages 315.
Crossref
Crossref
Jorge Jacinto, Pasquale Varriale, Emilie Pain, Andreas Lysandropoulos & Alberto Esquenazi. (2020) Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity. Frontiers in Neurology 11.
Crossref
Crossref
Christina Marciniak, Michael C. Munin, Allison Brashear, Bruce S. Rubin, Atul T. Patel, Jaroslaw Slawek, Angelika Hanschmann, Reinhard Hiersemenzel & Elie P. Elovic. (2020) IncobotulinumtoxinA Treatment in Upper‐Limb Poststroke Spasticity in the Open‐Label Extension Period of PURE: Efficacy in Passive Function, Caregiver Burden, and Quality of Life. PM&R 12:5, pages 491-499.
Crossref
Crossref
Anatol Kivi, Songjin Ri & Jörg Wissel. (2020) What clinicians and patients want: The past, the presence, and the future of the botulinum toxins. Toxicon 177, pages 46-51.
Crossref
Crossref
Thierry Deltombe, Thierry Lejeune & Thierry Gustin. (2019) Botulinum toxin type A or selective neurotomy for treating focal spastic muscle overactivity?. Annals of Physical and Rehabilitation Medicine 62:4, pages 220-224.
Crossref
Crossref
Christina Marciniak, Michael C. Munin, Allison Brashear, Bruce S. Rubin, Atul T. Patel, Jaroslaw Slawek, Angelika Hanschmann, Reinhard Hiersemenzel & Elie P. Elovic. (2018) IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study. Advances in Therapy 36:1, pages 187-199.
Crossref
Crossref
Sheng Li & Gerard E. Francisco. 2021. Botulinum Toxin Therapy. Botulinum Toxin Therapy
127
146
.
Alessio Baricich, Alessandro Picelli, Andrea Santamato, Stefano Carda, Alessandro de Sire, Nicola Smania, Carlo Cisari & Marco Invernizzi. (2018) Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment. Clinical Drug Investigation 38:11, pages 991-1000.
Crossref
Crossref
Jörg Wissel. (2018) Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity – Insights from recent studies. Toxicon 147, pages 100-106.
Crossref
Crossref
Giancarlo Ianieri, Riccardo Marvulli, Giulia Gallo, Pietro Fiore & Marisa Megna. (2018) “Appropriate Treatment” and Therapeutic Window in Spasticity Treatment with IncobotulinumtoxinA: From 100 to 1000 Units. Toxins 10:4, pages 140.
Crossref
Crossref
Jörg WisselDjamel BensmailJoaquim J. FerreiraFranco MolteniLalith SatkunamSusana MoraledaTiina RekandJohn McGuireAstrid ScheschonkaBirgit Flatau-BaquéOlivier SimonEdward T.J. RochfordDirk DresslerDavid M. SimpsonStephen McNeil, Isabelle Laffont, Frédéric Pellas, Manuel Dafotakis, Markus Ebke, Martin Hecht, Peter Kossmehl, David Liebetanz, Friedemann Müller, Iris Reuter, Walter Raffauf, Tobias Wächter, Sergio Barbieri, Alessio Baricich, Mario Basciani, Giancarlo Ianieri, Maurizio Osio, Francesco Sciarrini, Nicola Smania, Tiina Ader, Luisa Medeiros, Montserrat Abenoza Guardiola, Josefina Junyent Pares, Lourdes López de Munaín, Marina Tirado, François Bethoux, William Bockenek, Shashank Davé & Bruce Rubin. (2017) Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity. Neurology 88:14, pages 1321-1328.
Crossref
Crossref
Uwe Klaus Zettl, Ulrike Bauer-Steinhusen, Thomas Glaser, Klaus Hechenbichler & Michael Hecker. (2016) Comparative evaluation of patients’ and physicians’ satisfaction with interferon beta-1b therapy. BMC Neurology 16:1.
Crossref
Crossref
John Fezza, John Burns, Julie Woodward, Daniel Truong, Thomas Hedges & Amit Verma. (2016) A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm. Journal of the Neurological Sciences 367, pages 56-62.
Crossref
Crossref
Elie Paul Elovic, Michael C. Munin, Petr Kaňovský, Angelika Hanschmann, Reinhard Hiersemenzel & Christina Marciniak. (2015) Randomized, placebo‐controlled trial of incobotulinumtoxina for upper‐limb post‐stroke spasticity. Muscle & Nerve 53:3, pages 415-421.
Crossref
Crossref
Oluwadamilola O. Ojo & Hubert H. Fernandez. (2015) Is it time for flexibility in botulinum inter-injection intervals?. Toxicon 107, pages 72-76.
Crossref
Crossref
Matthias Wittstock. (2015) Behandlungszufriedenheit bei Spastizit?t nach Schlaganfall. DNP - Der Neurologe und Psychiater 16:5, pages 22-23.
Crossref
Crossref